BelgiumTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.054 (0.052–0.055) 0.47 (0.46–0.49)
Mortality (HIV+TB only) 0.011 (<0.01–0.055) 0.1 (0–0.49)
Incidence  (includes HIV+TB) 1.1 (0.92–1.2) 9.4 (8.1–11)
Incidence (HIV+TB only) 0.084 (0.069–0.099) 0.74 (0.61–0.88)
Incidence (MDR/RR-TB)** 0.023 (<0.01–0.038) 0.2 (0.08–0.34)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.028 (0.013–0.044) 0.35 (0.23–0.46) 0.38 (0.25–0.51)
Males 0.041 (0.028–0.055) 0.65 (0.51–0.79) 0.69 (0.54–0.84)
Total 0.07 (0.052–0.088) 1 (0.91–1.1) 1.1 (0.92–1.2)
TB case notifications, 2015  
Total cases notified 988
Total new and relapse 928
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status 46%
          - % pulmonary 70%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.04–0.1)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 30 7%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  16
(6–26)
Estimated % of TB cases with MDR/RR-TB 1.6% (0.66–3.3) 8.8% (1.9–24)  
% notified tested for rifampicin resistance 60% 70% 775
MDR/RR-TB cases tested for resistance to second-line drugs   15
Laboratory-confirmed cases MDR/RR-TB: 17, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 867
Previously treated cases, excluding relapse, registered in 2014 73% 70
HIV-positive TB cases, all types, registered in 2014 71% 34
MDR/RR-TB cases started on second-line treatment in 2013 79% 14
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data